Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA

Bacteremia due to Methicillin-Resistant Staphylococcus aureus

(2016) Marisa Holubar et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Empirical therapy in Methicillin-resistant Staphylococcus Aureus infections: An Up-To-Date approach

(2016) Alison S. VanEperen et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Exposure to Ceftobiprole Is Associated with Microbiological Eradication and Clinical Cure in Patients with Nosocomial Pneumonia

(2014) A. E. Muller et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Phase 3 Randomized Double-Blind Comparison of Ceftobiprole Medocaril Versus Ceftazidime Plus Linezolid for the Treatment of Hospital-Acquired Pneumonia

(2014) S. S. Awad et al.   CLINICAL INFECTIOUS DISEASES

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions

(2014) Jason A Roberts et al.   LANCET INFECTIOUS DISEASES

Monte Carlo Simulations Based on Phase 1 Studies Predict Target Attainment of Ceftobiprole in Nosocomial Pneumonia Patients: a Validation Study

(2013) Anouk E. Muller et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Treatment of bacteraemia: meticillin-resistant Staphylococcus aureus (MRSA) to vancomycin-resistant S. aureus (VRSA)

(2013) I.M. Gould   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types

(2013) David J. Farrell et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Antimicrobial activity of ceftobiprole against Gram-negative and Gram-positive pathogens: results from INVITA-A-CEFTO Brazilian study

(2012) Rosângela Ferraz Cereda et al.   Brazilian Journal of Infectious Diseases

A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation

(2012) Susan C. Nicholson et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

(2011) A.-P. Magiorakos et al.   CLINICAL MICROBIOLOGY AND INFECTION

Penetration of Anti-Infective Agents into Pulmonary Epithelial Lining Fluid

(2011) Keith A. Rodvold et al.   CLINICAL PHARMACOKINETICS

In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007–2009 study

(2011) Andrew Walkty et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

In vitro activity of ceftobiprole against meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA)

(2010) Louis D. Saravolatz et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In vitro bactericidal activity of ceftobiprole against hospital- and community-associated methicillin-resistant Staphylococcus aureus

(2010) S. Borbone et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro activity of ceftobiprole against Gram-positive and Gram-negative bacteria isolated from humans and animals

(2010) N. Silva et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacodynamic Profiling of Ceftobiprole for Treatment of Complicated Skin and Skin Structure Infections

(2009) H. Kimko et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Identifying Exposure Targets for Treatment of Staphylococcal Pneumonia with Ceftobiprole

(2009) K. A. Rodvold et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Soft-Tissue Penetration of Ceftobiprole in Healthy Volunteers Determined by In Vivo Microdialysis

(2009) A. Barbour et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Pharmacodynamics of Ceftobiprole, an Anti-MRSA Cephalosporin with Broad-Spectrum Activity

(2009) Bindu Murthy et al.   CLINICAL PHARMACOKINETICS

In Vitro Activity of Ceftobiprole against Pathogens from Two Phase 3 Clinical Trials of Complicated Skin and Skin Structure Infections

(2008) K. M. Amsler et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamic Characterization of Ceftobiprole in Experimental Pneumonia Caused by Phenotypically Diverse Staphylococcus aureus Strains

(2008) S. Laohavaleeson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetic Analysis of Ceftobiprole for Treatment of Complicated Skin and Skin Structure Infections

(2008) H. Kimko et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activities of Ceftobiprole, Linezolid, Vancomycin, and Daptomycin against Community-Associated and Hospital-Associated Methicillin-Resistant Staphylococcus aureus

(2008) S. N. Leonard et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vivo Pharmacodynamics of Ceftobiprole against Multiple Bacterial Pathogens in Murine Thigh and Lung Infection Models

(2008) W. A. Craig et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Randomized, Double-Blind Trial Comparing Ceftobiprole Medocaril with Vancomycin plus Ceftazidime for the Treatment of Patients with Complicated Skin and Skin-Structure Infections

(2008) G. J. Noel et al.   CLINICAL INFECTIOUS DISEASES

In vitro activity of ceftobiprole, linezolid, tigecycline, and 23 other antimicrobial agents against Staphylococcus aureus isolates in China

(2008) Hui Wang et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Antimicrobial activity of ceftobiprole, a novel anti–methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005–2006)

(2008) Thomas R. Fritsche et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent Gram-positive and Gram-negative isolates of European origin

(2008) C. M. Pillar et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY